Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 8*)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box  ☐.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

EXPLANATORY NOTE

This Amendment No. 8 (the “Amendment”) to Schedule 13D is being filed with the Securities and Exchange Commission (the “SEC”) on behalf of OPKO Health, Inc., a Delaware corporation (“OPKO”) and relates to the Class A common stock, par value $0.0001 per share (“GeneDx Common Stock”), of GeneDx Holdings Corp., a Delaware corporation (“GeneDx” or the “Issuer”) and amends and supplements the initial statement on Schedule 13D filed by OPKO with the SEC on May 9, 2022, as amended by Amendment No. 1 to Schedule 13D filed with the SEC on February 3, 2023, as amended by Amendment No. 2 filed with the SEC on April 20, 2023, as amended by Amendment No. 3 filed with the SEC on July 5, 2024, as amended by Amendment No. 4 filed with the SEC on July 26, 2024, as amended by Amendment No. 5 filed with the SEC on August 12, 2024, as amended by Amendment No, 6 filed with the SEC on August 23, 2024, as amended by Amendment No, 7 filed with the SEC on September 18, 2024    (the “Schedule 13D”).  Capitalized terms used but not defined in this Amendment No. 8 shall have the same meanings ascribed to them in the Schedule 13D. 

Item 4 is amended by adding the following paragraph to the end of the item:

In a series of transactions between November 4, 2024 and November 8, 2024, OPKO sold a total of 310,000 shares of GeneDx Common Stock on the open market at prices ranging from $74.90 to $80.00 per share for an aggregate sale price of approximately $32,850,791.

Item 5 is deleted in its entirety and replaced with the following text:

(a)          The Company’s beneficial ownership of GeneDx Common Stock is as set forth in the table below:

______________

(b)          Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5.

(c)          In the last 60 days prior to the filing of this Amendment No. 8, OPKO sold a total of 618,666 shares of GeneDx Common Stock on the open market at prices ranging from $33.00 to $80.00 per share for an aggregate sale price of approximately $44,176,226. Sales of GeneDx Common Stock prior to September 18, 2024 were previously reported in Amendment No. 4, Amendment No. 5, Amendment No. 6, and Amendment No. 7. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days.

(d)          Except as described herein, no other person is known by OPKO to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of the Issuer beneficially owned by them.

(e)          Not applicable.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.